Phaseline

Companies › Sumitomo Pharma America

Sumitomo Pharma America: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Neurology, Ophthalmology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nuvisertib (TP-3654)
PIM kinase inhibitor
PIM1, PIM2, PIM3Phase 1MyelofibrosisApr 2027
Enzomenib (DSP-5336)
Menin inhibitor
MEN1Phase 1Leukemia, Myeloid, AcuteJun 2027
DSP-3077 Retinal Sheet
Retinal cell therapy (photoreceptor replacement)
–Phase 1Retinitis PigmentosaOct 2028
SMP-3124LP
Liposomal encapsulation formulation of SMP-3124
–Phase 1Solid TumorDec 2028
DSP-1083
Cell implant
–Phase 1Parkinson's DiseaseDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04176198Nuvisertib (TP-3654)Phase 1MyelofibrosisOncologyApr 2027
NCT04988555Enzomenib (DSP-5336)Phase 1Leukemia, Myeloid, AcuteOncologyJun 2027
NCT06891885DSP-3077 Retinal SheetPhase 1Retinitis PigmentosaOphthalmologyOct 2028
NCT06526819SMP-3124LPPhase 1Solid TumorOncologyDec 2028
NCT06753331DSP-1083Phase 1Parkinson's DiseaseNeurologyDec 2030

Targets

MEN1 (1) PIM1 (1) PIM2 (1) PIM3 (1)

Companies with the same targets

Ryvu Therapeutics Biomea Fusion Kura Oncology Syndax Pharmaceuticals Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.